Bioventus (NASDAQ:BVS – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.750-0.790 for the period, compared to the consensus estimate of 0.780. The company issued revenue guidance of $590.0 million-$595.0 million, compared to the consensus revenue estimate of $604.6 million.
Bioventus Stock Down 16.8%
Bioventus stock opened at $10.94 on Wednesday. The company’s 50-day moving average price is $13.62 and its two-hundred day moving average price is $10.92. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The stock has a market cap of $919.97 million, a P/E ratio of 13.67, a P/E/G ratio of 1.68 and a beta of 0.66. Bioventus has a twelve month low of $6.47 and a twelve month high of $15.89.
Bioventus (NASDAQ:BVS – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.17. Bioventus had a return on equity of 27.52% and a net margin of 9.78%. The company had revenue of $142.44 million during the quarter. As a group, analysts expect that Bioventus will post 0.79 EPS for the current year.
Analyst Ratings Changes
Several analysts recently issued reports on BVS shares. Craig Hallum restated a “buy” rating and issued a $18.00 price target on shares of Bioventus in a research note on Thursday, August 6th. Barrington Research set a $18.00 price objective on Bioventus in a report on Thursday, August 6th. Weiss Ratings upgraded Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Canaccord Genuity Group dropped their target price on Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of Bioventus in a report on Monday, August 17th. Six research analysts have rated the stock with a Buy rating. According to MarketBeat, Bioventus currently has a consensus rating of “Buy” and an average price target of $16.60.
Check Out Our Latest Research Report on Bioventus
Trending Headlines about Bioventus
Here are the key news stories impacting Bioventus this week:
- Positive Sentiment: Q3 adjusted EPS was $0.17, matching estimates and up from $0.15 a year earlier. Bioventus maintained its 2026 adjusted EPS guidance of $0.75–$0.79. Bioventus matches Q3 earnings estimates
- Neutral Sentiment: Canaccord Genuity kept a Buy rating but lowered its price target to $18 from $19, signaling continued analyst optimism alongside a more cautious valuation. Canaccord Genuity Group recommendations
- Negative Sentiment: Q3 revenue was $142.44 million, and reports cited a sales miss. More importantly, Bioventus forecast 2026 revenue of $590–$595 million, below the roughly $604.6 million consensus estimate. The reduced sales outlook was the main pressure on the shares. Bioventus reports higher Q3 profit, cuts 2026 sales outlook
- Negative Sentiment: Coverage also noted that debt paydown, rather than stronger operating performance, was a key driver of earnings growth, adding to concerns about the underlying business momentum. Bioventus matches EPS but cuts revenue outlook
Bioventus Company Profile
Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.
The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.
Read More
- Five stocks we like better than Bioventus
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
